For third item on front page news

Oxular in Drug Discovery World

An-excellent-summary-about-the-potential-of-our-lead-program-oxu-001-from-drug-discovery-world. “An innovative sustained release formulation of dexamethasone currently under investigation for use in DME offers the potential for effective anti-inflammatory treatment with significantly fewer injections and a high likelihood of fewer side effects, as its levels in the vitreous and anterior segment are minimal. This will limit the frequency of IOP elevation and cataract …

Oxular in Drug Discovery World Read More »

2 x Triesence doses; nearly one year of response

Oxular’s Senior Medical Advisor, Prof. Marc de Smet, presented on “Managing CME via the Suprachoroidal Space” at the December 2021 IOIS Conference. His talk included an update on a hard-to-treat post-surgical macular edema patient. The Oxulumis® posterior suprachoroidal microcatheter was used under compassionate-use for the administration of Triesence. The data below shows both a gain …

2 x Triesence doses; nearly one year of response Read More »

Scroll to Top